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Infiltration of the tumor microenvironment 
(TME) by immune and inflammatory cells is involved 
in promoting tumorigenesis, tumor progression, 
local invasion and metastasis.(1) Tumor-associated 
macrophages (TAMs), a prominent and abundant 
inflammatory component of solid and hematological 
malignancies, express a pro- and anti-tumor effect 
in all stages of carcinogenesis. The molecular and 
functional phenotype of TAMs plays a key role in the 
tumorigenesis and progression.(2) A malignant tumor 
contains not merely proliferating neoplastic cells, but 
many other cells which constitute a microenvironment, 
for example, endothelial cells, ſ broblasts, and inſ ltrating 
immune cells. TAMs, one of the important infiltrating 
immune cells, secrete an array of cytokines, chemokines, 
and enzymes that affect tumor progression, metastasis, 
and resistance to therapy.(3,4) TAMs secrete an array of 
cytokines, chemokines, and enzymes that affect tumor 
progression, metastasis, and resistance to therapy.(5-7) 
Clinical success in targeting macrophage (M) in tumor 
patients suggests that TAMs might by attractive targets 
in combination therapy for tumor treatment.(8,9)
Chinese medic ine (CM) is  an important 
complementary medicine parallel to the conventional 
medicine system for tumor patients in China and other 
Asian countries. Chinese materia medica (CMM) is 
the natural therapeutic agent used under the guidance 
of CM theories.(10) CMM therapies are a long-term 
clinical practice, and share the characteristics of 
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multi-component, multi-targeted and dual-regulatory 
function.(11) One of the mechanisms of CMM tumor 
therapy is related to regulating the internal environment 
and remodeling the TME, which coincides with 
conventional tumor therapy targeting the TME. CMM 
prescriptions, consisting of a single herb or combination 
of several herbs based on the theory of CM, have been 
used for treating and preventing various cancers during 
long-term popular practice or in combination therapy with 
chemotherapeutics.(7,12,13) The potential mechanism of 
anti-tumor effects of CMM includes increasing the efſ cacy 
of the therapeutic effect of chemotherapeutics including 
decreasing the development of chemoresistance 
or regulating the immune system.(14-16) It has been 
shown that CMMs have the effects of enhancing the 
immunological surveillance, regulating the body's internal 
milieu and remodeling the TME.(13) 
In this article, we briefly introduce the origin, 
subpopulations, phenotypic characteristics and 
polarization of TAM and the TAM's effect on the TME 
in promoting tumorigenesis, metastasis, and immune 
suppression. Speciſ cally we analyzed the effects and 
mechanisms of CMM prescriptions, extracts or active 
compounds on targeting TAMs in anti-tumor therapies. 
We also discuss the CMM's dual-regulatory and multi-
targeting functions on regulating TAM, and hopefully, 
provide the theoretical basis for CMM use in clinical 
practice for cancer therapy.
Origin, Subpopulation and Polarization of TAM
Ms involved in the immune responses appear 
to generate from circulating bone marrow monocytes, 
and are recruited to the TME by cytokines secreted by 
the tumor cells and other cells, then differentiated into 
various phenotypes and functions including anti- or 
pro-tumor activities.(5,17,18) 
Subpopulations of M
In in vitro models, Ms have been classiſ ed as pro-
inflammatory, classically activated Ms (M1) and anti-
inƀ ammatory; alternatively activated Ms (M2) based on 
their cell surface phenotypes and secreted cytokines.
M1-type Ms, induced by Th1 mediators such as 
interferory (IFN)-¢, tumor necrosis foctor   (TNF- ) 
or lipopolysaccharides (LPS), release pro-inƀ ammatory 
cytokines such as interleukin (IL)-12, IL-23. They 
express major histocompatibility complex (MHC) ĉ 
molecules, and have a high IL-12/IL-10 secretion ratio. 
M1 Ms participate in the Th1 inƀ ammatory responses 
primarily through production of pro-inflammatory 
mediators and up-regulation of cell surface molecules 
necessary for antigen presentation to activate Th1 cells 
and enhance the ability to phagocytose pathogenic 
material.(19,20) M2-type Ms, typically induced by Th2 
cytokines, mediate resistance to parasites, mediate 
immune regulation and tissue repair.(4,21) M2 Ms 
release high levels of IL-10 and low levels of IL-12 
and IL-23. In the context of cancer, however, M2 Ms 
help driving tumor growth through the promotion of 
angiogenic programs, tissue remodeling, and directly or 
indirectly suppress cytotoxic T cell activity.(22)
The classiſ cation of Ms in type M1 versus type 
M2 is an oversimpliſ cation of the in vivo situation. Most 
recently, Mosser and colleagues(23) suggested a new 
grouping of M populations based on fundamental 
M functions. This form of classification, though it 
may better reflect the heterogeneity and plasticity of 
Ms in the TME, is clearly more difſ cult to consider 
and apply to research. The classical classiſ cation in 
M1/M2 Ms is still commonly used as a valid and 
accepted concept for the sake of clarity.(2)
Polarization of M
Ms can be phenotypically polarized into diverse 
functional phenotypes by different microenvironment, 
and could have different effects during early or late 
tumor progression.(24) Tumor escape has been linked to 
a polarization switch from M1 to M2 M phenotypes. 
In the early steps of tumor initiation, TAMs were mostly 
polarized towards a M1-like phenotype while during later 
steps of tumor progression they polarized mostly toward 
a M2-like phenotype.(24,25) In contrast, Wang, et al(26) 
reported a pro-metastatic role of M1-like TAM (CD68+ 
HLA-DR+) in hepatocellular carcinoma. This difference 
may be due to the different and complex environments 
of various cancers observed in vivo, which cannot yet 
be easily simulated in vitro. Many chemokines, such as 
C-X-C motif chemokine 12 (CXCL12),(27) and chemokine 
ligand 2 (CCL2),(28) signaling pathways, such as nuclear 
factor ©B (NF-©B),(29) Notch receptors,(30) or hypoxia 
present in the TME(28) contribute to the polarization of 
TAM. The details of TAM function and CMM targeting 
Ms will be presented below.
Effects of TAMs during Carcinogenesis and Anti-
tumor Mechanisms of CMM Targeting TAMs
Many observations indicate that TAMs possess 
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M2-associated pro-tumor functions, including the 
induction of tumor angiogenesis and the stimulation 
of tumor cell proliferation, survival and invasion by 
producing inflammatory mediator, such as cytokines, 
and matrix metalloprotease (MMPs), or suppressing the 
cytotoxic effect of T cells.(2,31) TAMs play an important 
role in growth, metastasis and immunosuppression. 
Recently, studies showed that "TAM-speciſ c therapies" 
may be a suitable option for further therapeutic 
approaches in cancer. Thus, CMM targeting TAMs 
may be considered as an additional anti-tumor therapy 
applicable to multiple stages of carcinogenesis.(19,32)
Tumor Initiation
It is now widely accepted that the nonmalignant 
cells of the TME evolve along with the growing tumor 
and provide essential cues supporting the modulation of 
TAM phenotype.(5) Chronic inƀ ammation was shown to be 
associated with the development of malignant tumors by 
creating a tumor-promoting microenvironment.(33) Ms 
are recruited to different areas of the TME and educated 
toward different phenotypes.(17,18) It has been shown that 
pancreatic cancer cells could activate Ms in vitro to 
polarize toward an M2-phenotype, through the cytokines 
IL-4, IL-10 and CCL2.(34,35) This effect was conſ rmed by 
in vivo results revealing about 90% of all TAMs to be M2 
Ms. Accordingly, depletion of Ms in vivo resulted in a 
signiſ cantly reduction in tumor growth.(36) Some Chinese 
herbal ingredients or prescriptions have been conſ rmed 
to effectively inhibit the recruitment and activation of Ms 
to tumor sites and to re-educate TAM (see below).
Recruitment and Activation of TAMs
Diverse cytokines and polypeptides produced by 
tumor cells as well as microenvironment, such as hypoxia, 
are involved in guiding the recruitment, positioning and 
function of TAMs in the TME.(3) For example, CCL2, plays 
a pivotal role in many cancers, including pancreas, ovary, 
and breast in the recruitment and inſ ltration on M into 
the TME.(34,35,37) In a pancreatic cancer mouse model, the 
inhibition of CCL2 was shown to reduce the recruitment 
of TAMs into the tumor, to improve the response to 
gemcitabine and increase the antitumor T-cell response 
and further inhibit tumor metastasis.(37,38)
CMM may regulate the recruitment and activation 
of Ms in the TME by various pathways. Berberine, 
an isoquinoline alkaloid isolated from many medicinal 
herbs, such as Coptis chinensis Franch, inhibited the 
growth of CT26 tumor cells implanted subcutaneously 
in BABL/c mice and signiſ cantly reduced the density 
of CD68+/CD206+ TAMs. This is consistent with the 
notion that the anti-tumor effect of berberine involves 
inhibition of TAMs recruitment.(39,40) Epigallocatechin 
gallate (EGCG), a polyphenol present in green tea, 
inhibited tumor growth in a murine breast cancer 
model by inhibiting TAM infiltration and M2 M 
polarization.(41,42) Praeruptorin D and E, the main 
constituents of Peucedanum praeruptorum Dunn, 
could protected BALB/c mice from lipopolysaccharide 
(LPS)-induced acute lung injury by inhibiting Ms 
inſ ltration to the lung, cytokine release and vascular 
permeability.(43) Polysaccharopeptide (PSP), from 
Coriolus versicolor  demonstrated anti-tumor and 
immune regulating effects.(44,45) PSP significantly 
increased the number of CD14+/CD16+ monocytes 
in phytohemagglutinin treated peripheral blood 
mononuclear cell model, but could not affect the 
proliferations of T-cells, natural killer, and B-cells. 
Thus, stimulating monocyte/M with PSP could be an 
effective therapeutic intervention in targeting tumors.(46) 
As t raga lus  po lysacchar ides  (APS) ,  the 
polysaccharide fraction of the roots of Astragalus 
membranaceous, were reported to activate Ms 
in a toll-like receptor 4 (TLR4)-dependent manner 
while activating B cells via membrane Ig in a TLR4-
independent manner.(45) Abrus agglutinin is a low-
toxicity protein from the plant Abrus precatorius L. 
In its native (NA) and heat-denatured (HDA) forms, 
it activated TAMs in Dalton's lymphoma-bearing mice, 
and significantly increased in vitro cytotoxicity against 
tumor cells and stimulated production of nitric oxide 
but not of TNF- . Thus, NA and HDA could be 
used as regulators of TAMs, for the treatment of 
cancer.(47) KSG-002, a 30% ethanolic extract of 
Astragalus membranaceous and Angelica Sinensis 
gigas at 3:1 w/w ratio, suppressed xenograft tumor 
growth and pulmonary metastasis via inhibiting TAM 
recruitment by blocking NF-©B-dependent TNF-  
production.(48) Qinghao Biejia Decoction (᭟ᗦᲑႁ෋, 
QHBJ), a classical prescription consisting of Artemisia 
apiacea, turtle shell, Rehmannia glutinosa Libosch., 
Anemarrhena asphodeloides  Bge. and Paeonia 
suffruticosa Andr, significantly reduced the incidence 
rate of dimethylbenzanthracene (DMBA)-induced 
ovarian cancer in rats, inhibited the infiltration of 
TAMs in ovarian tumors and down-regulated the 
expression of inƀ ammatory mediators prostaglandin E2 
(PGE2) and leukotriene B4 (LTB4) and the angiogenic 
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factor vascular endothelial growth factor (VEGF) in 
ovarian tumor tissues.(49) Shaoyao Decoction (ᓱᕲ෋), 
a classical CMM prescription of Paeonia lactiƀ ora Pall 
effective in treating ulcerative colitis, could signiſ cantly 
increase the survival of mice with azoxymethane 
(AOM)/dextran sodium sulfate (DSS)-induced colitis-
associated colorectal cancer (CA-CRC) by reducing 
the infiltration of TAM and thereby decreasing 
the expression levels of serum IL-1¡, IL-6, and 
TNF- .(48) PHY906 (KD018), a CMM prescription 
consisting of Glycyrrhiza uralensis Fisch, Paeonia 
lactiflora Pall, Scutellaria baicalensis Georgi, and 
Ziziphus jujuba Mill, may potentiate sorafenib action 
by up-regulating the expression of CCL2, which could 
attract M1-type Ms and exert an anti-tumor activity.(49)
Re-programing of TAM Phenotype
Mantovani proposed that TAM exert pleiotropic 
functions that can influence tumor growth and 
progression in opposite directions.(35) Recently, 
researches confirmed that circulating monocytes 
were recruited to the TME by chemotactic factors 
produced by tumor cells and differentiated toward the 
M2 phenotype.(52-54) M2 Ms release various growth 
factors and cytokines to promote tumor cell invasion, 
induce angiogenesis, suppress antitumor immunity, 
and accelerate tumor cell metastasis.(55,56) The 
polarization of TAM was a regulated and reversible 
process and dependent on the TME. It was shown 
that a predominance activation of NF-©B and signal 
transducers and activators of transcription (STAT) 1 
promoted M1 M polarization resulting in cytotoxic 
and inƀ ammatory activities, while STAT3 and STAT6 
activation resulted in M2 M polarization leading to 
immune suppression and tumor progression.(57,58)
CMM targeting TAMs could act as an anti-tumor 
prescription by aiming at preventing polarization of 
TAMs toward a more anti-tumor phenotype. Emodin, a 
natural anthraquinone derivative isolated from Rheum 
palmatum L., inhibited M recruitment and M2 
polarization by suppressing STAT6 phosphorylation 
and C/EBPB expression in the 4T1 and EO771 
orthotopic breast cancer mouse models. (59,60) 
Isoliquiritigenin (ISL), a flavonoid from Glycyrrhiza 
uralensis Fisch, inhibited M2 M polarization by 
down-regulating PGE2 and IL-6-mediated signaling 
in a mouse model of AOM/DSS-induced colitis-
associated tumorigenesis. In parallel, ISL also blunted 
the M2 polarization of RAW264.7 cells and mouse 
peritoneal Ms by inactivating PGE2/peroxisome 
proliferator-activated receptor £ and IL-6/STAT3 
signaling in vitro.(61) Sinomenine, an alkaloid extracted 
from Sinomenium Acutum, has been used to treat 
rheumatism in China. Zhang, et al(62) found that treating 
breast cancer-bearing mice with 100 mg/kg sinomenine 
hydrochloride (SH) can provide a self-reinforcing 
stimulus for further polarizing TAMs away from an 
M2-like phenotype toward an M1-like phenotype 
thereby contributing to its anti-tumor and anti-metastasis 
effect. The aqueous extract of Crinum latifolium L. leaf 
induced expression of TNF- , IL-1¡ and IL-6 and 
promoted Ms differentiation into the pro-inƀ ammatory 
M1 phenotype.(63) The Sarcandra glabra polysaccharide 
(SGP) could effectively increase expression of CD14, 
CD16/32 and CD40 in Ms induced by IFN-¢, which 
indicated the potential for applications in regulating the 
immune balance in the treatment of cancer.(64) Fuzheng 
Jiedu Decoction (੺൤ᝍඉ෋, FZJD), a prescription 
consisting of Astragalus membranaceous, Codonopsis 
pilosula, Atractylodes macrocephala, Lycium barbarum, 
Smilax glabra, Polygonum multiflorum, and Actinidia 
arguta, reduced the expression of the M2 Ms speciſ c 
genes Arg-1 (an immunosuppressive enzyme) and 
CCL22 (a chemotactic chemokine) in an in vitro 
co-culture system of RAW264.7 Ms and mesenchymal 
stem cells.(13) FZJD combined with 5-ƀ uorouracil (5-FU) 
inhibited the marker of M2 Ms subtype expression and 
increased the marker of M1 Ms subtype expression, 
resulting in the inhibition of tumor recurrence and 
metastasis in a gastric cancer model.(65)
In some excessive inflammatory reactions, active 
CMM components could promote phenotype transition 
from M1 to M2, thus acting as anti-inflammation drug. 
Berberine down-regulated the content of TNF-  and 
the mRNA expression levels of inducible nitric noxide 
synthase (iNOS) and suppressor of cytokin signaling 
(SOCS) 3 in Ms induced by LPS, inhibited the content 
of IL-10 and the mRNA expression level of Arg-1 in 
Ms induced by IL-4, but did not modify SOCS2. The 
results indicate that berberine has an effect on inhibiting 
the M1 and M2 polarization of Ms in vitro and may 
play a regulatory role in the dynamic balance of M1/M2 
phenotype.(66) The similar results were found in many 
compounds or CM prescription, such as curcumin,(67) 
arctigenin,(68) and Xuebijing Injection (ᛞॹьฌ࠱๯).(52) 
Importantly, CMM can act in a dual-regulatory 
function in the inƀ ammatory reaction depending on the 
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specific physiological or pathological processes and 
the tissues involved. CMM can suppress excessive 
inƀ ammation, while promoting the polarization of anti-
inflammatory M2 Ms into M1 phenotype thereby 
altering the state of immuno-suppression in the TME 
of advanced cancers. 
Tumor Metastasis
The process of metastasis represents a critical 
phase in the neoplastic cascade, and growing evidence 
indicate a tight link between metastasis and TAMs, 
whereby TAMs produce inflammatory cytokines, 
stimulate the growth of tumor cells and promote tumor 
cell migration and metastasis. TAMs contribute to 
tumor progression also by producing several factors 
enhancing angiogenesis and lymphogenesis.(34,69)
TAMs  have  been  repo r t ed  t o  p romo te 
angiogenesis via the production of diverse pro-
angiogenic factors such as transforming growth 
factor-¡ (TGF-¡), VEGF, Platelet derived growth 
factor (PDGF), fibroblast growth factor (FGF) and 
angiogenic chemokines, such as CXCL12.(70,71) 
They also regulate matrix degradation through the 
production of matrix-degrading enzymes such as 
MMPs, plasmin, and urokinase-type plasminogen 
activator (uPA).(69,72) Clinical research has confirmed 
that M2-polar ized TAMs are associated with 
poor prognoses in several cancers, including 
classical Hodgkin's lymphoma (CHL), (73) lung 
adenocarcinoma,(74) and pancreatic cancer.(75) Ding, 
et al(76) found a significant correlation between the 
expression of CD68 or CD163 protein with a tumor 
size, lymph node metastasis, and vascular invasion 
in patients with pancreatic cancer consistent with the 
role of TAM inſ ltration in pancreas and the promotion 
of pancreatic cancer development.
Angiogenesis and Lymphangiogenesis
Angiogenesis and lymphangiogenesis are critical 
processes for tumor growth, invasion, and metastasis. 
TAMs promote angiogenesis in a wide type of tumors, 
such as gliomas, carcinomas of the esophagus, breast, 
bladder, and prostate by releasing vascular growth 
factors (mainly VEGF and PDGF), cytokines (e.g. 
TGF-¡), proteases, and chemokines.(77) TAMs support 
tumor lymphangiogenesis not only by secreting pro-
lymphangiogenic factors, such as VEGF-A and MMP-9, 
but also by trans-differentiation into lymphatic endothelial 
cells.(78) Wogonin, a flavonoid isolated from the root 
of Scutellaria baicalensis, inhibited tumor growth, 
metastasis, angiogenesis and lymphangiogenesis, 
and reduced the number of TAM in the tumors of 
LM8-bearing mice. Wogonin inhibited VEGF-C-induced 
lymphangiogenesis through the reduction of VEGF-C-
induced VEGF receptor-3 phosphorylation.(79) Recently 
a phenolic alkaloids of Menispermum dauricum (PAMD) 
inhibited BXPC-3 tumor growth and angiogenesis by 
reducing the production of VEGF, and basic ſ broblast 
growth factor (bFGF).(80) Many results show that 
genistein, a soy isoflavonoid, inhibited angiogenesis 
through the regulat ion of  VEGF, MMPs, and 
epidermal growth factor receptor expressions, thereby 
resulting in a strong anti-tumor effect.(81,82) Qingyi Huaji 
Decoction (ຍᑖӑሥ෋, QYHJ), consists of many 
herbs including the radics of Paeonia lactiflora Pall 
and Scutellaria baicalensis Georgi, has been used 
as an integrative agent in the clinical treatment of 
advanced pancreatic cancers, especially those with 
liver metastasis. QYHJ inhibited the growth of human 
pancreatic cancer cell line CFPAC-1 in vivo, and this 
correlated with the down-regulation of serum level of 
pro-angiogenic factors sVCAM-I, TNF- , bFGF, IL-6 and 
IL-8.(83) Besides, QYHJ exerted an inhibitory effect on 
the growth of experimental liver metastasis in nude mice 
inoculated intra-splenically with the human pancreatic 
cancer cell line SW1990, in part though the inhibition of 
VEGF and Cyr61 expression.(84) QYHJ inhibited cancer-
related inflammation in the SW1990HM (pancreatic 
tumor cell line with high metastasis) tumor model by 
decreasing inſ ltration of TAM and IL-6 production and 
resulting in the decreased epithelial-to-mesenchymal 
transition and cell invasion.(85) Hongjingtian Injection 
(ጚఀܹฌ࠱๯), a CMM standardized Tibetan herbal 
product extracted from Rhodiola crenulata L., used to 
treat patients with acute ischemic stroke or coronary 
heart disease, inhibited the metastasis of human 
non-small cell lung cancer by reducing the production 
of VEGF.(86)
Matrix Remodeling
In the tumor stroma, Ms can produce enzymes 
promoting matrix degradation, such as MMPs, uPA 
and uPA receptor, and plasmin, thereby facilitating 
invasion and metastasis of tumor cell.(34) Emodin 
exerts anti-proliferative and anti-metastatic activity 
in pancreatic cancer both in vitro and in vivo, which 
may be related to the down-regulation of NF-©B and 
its regulated molecules survivin and MMP-9.(87) Gallic 
acid and gallic acid dimmer, polyphenols extracted 
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from pericarp of water caltrop, significantly decreased 
MMP-9 activity and inhibited migration of gastric cancer 
cells; TNF-  and IL-6 associated with migration and 
angiogenesis were also significantly reduced.(88) Aloe 
emodin, an anthraquinone from Rheum palmatum L., 
has anti-migratory and anti-angiogenic activities in colon 
cancer cells by down-regulating expression of MMP-
2/9, RhoB and VEGF.(89) Honokiol, a major phenolic 
compound isolated from the root and stem bark of 
magnolia, inhibited the expression of MMP-9 in PANC-
1 cells in vitro and VEGF in tumor tissue in vivo in an 
athymic mouse tumor model.(90)
Immune Suppression
TAMs also produce various immune suppressive 
factors, including PGE2, indoleamine 2,3-dioxygenase, 
Arg-1, and IL-10 to suppress tumor-associated 
antigen-specific T cell immunity and thus contribute 
to immunosuppression.(31,34) The major immune 
stimulatory cytokine IL-12 may be due to the activity 
of IL-10, produced either by TAM or by the tumor 
cells. Part of the immune suppressive activity of TAM 
is exerted indirectly by their release of chemokines, 
such as CCL18 and CCL22 that preferentially attract 
T cell subsets devoided of cytotoxic functions.(91) 
These immune stimulatory cytokines and chemokines 
could be the potential targets of anti-tumor CMM. 
Different reports indicate that polysaccharides from 
CMM herbs could improve the amount of Ms in the 
TME, enhance phagocytosis, as well as stimulate the 
secretion of NO, TNF- , IL-1, etc., possibly related 
with M1 Ms activation and polarization.(92)
Direct Effect on Ms
PAC-I, a mannose-rich polysaccharide fraction 
from Aloe vera  L. var. chinensis (Haw) Berg., 
increased the expression of MHC-ĉ and Fc¢R, and 
enhanced endocytosis, phagocytosis, NO production, 
TNF-  secretion and tumor cell cytotoxicity in vitro, 
stimulated systemic TNF-  production in vivo and 
prolonged the survival of tumor-bearing mice. The 
results may have therapeutic implications of PAC-I in 
tumor immunotherapy.(93)
Regulation of Immune System
Salidroside, an active component of Rhodiola rosea 
L., promoted proliferation and phagocytosis of peritoneal 
Ms stimulated by LPS and IFN¢, and reduced the 
production of reactive oxygen species, but promoted 
the production of NO, and in activated peritoneal 
Ms.(94) Li, et al(95) demonstrated that berberine 
inhibited the proliferation of Ishikawa endometrial 
carcinoma cancer cells co-cultured with TAM and the 
production of IL-8, while blocking NF-©B signaling 
pathway to restrain metastasis formation. Cucurbitacin 
D, an oxygenated tetracyclic triterpenoid isolated from 
Trichosanthes kirilowii, increased LPS-induced IL-1¡ 
production in culture supernatant of Ms, indicating 
that cucurbitacin D could initiate immune regulating 
activity in Ms and possibly function as anti-tumor 
drug.(96) 20S-dihydroprotopanaxadiol, a protopanaxadiol 
derivative found in Panax ginseng exhibiting various 
biological activities including anti-cancer, pro-apototic, 
and anti-inƀ ammatory effects, boosted innate immune 
responses of monocytes and Ms.(97) Garlic lectin was 
shown to induce IL-12 production via activation of p38 
MAPK/ERK in mouse Ms and to stimulate IFN-¢ 
production in spleen cells, consistent with anti-tumor 
effects.(98) Many studies showed that polysaccharides 
could enhanced cytotoxic and phagocytic activities 
of immune cells and increased the productions of 
many Th1 cytokines via various signaling pathways, 
such as Panax ginseng Polysaccharide,(99) B. striata 
Polysaccharide,(100,101) Polyporus polysaccharide,(102,103) 
Plantago asiatica L. Polysaccharide,(104) Ganoderma 
lucidum Polysaccharide.(105) These effects induced anti-
cancer effect indirectly though the activation of immune 
cells rather than via direct cytotoxic effects.(106,107) Water-
soluble polysaccharide extracted from Sanguisorba 
ofſ cinalis L., signiſ cantly inhibited the growth of mouse 
transplanted tumor, remarkably increased the spleen 
index and promoted splenocytes proliferation, M 
phagocytosis and secretion of serum cytokines IL-2, 
TNF-  and IFN-¢ in sarcoma 180-bearing mice in the 
absence of direct cytotoxic activity on tumor cells. These 
results indicated that the anti-tumor activity of SOP may 
be achieved through immune potentiation.(108) These 
results were confirmed by other researchers using 
different CMM, such as polysaccharide from Limonium 
sinense Kuntez,(109) Lilium sp.,(110) G. lucidum(111) and 
Weikangfu Granule (ᐽकܭᑛٺ), a drug preparation 
used to treate gastric cancer and consisting of Curcuma 
wenyujin, Astralagus membranaceous, Glycyrrhiza 
inƀ ate, Poria coco,(112) and Shenqi Fuzheng Injection (Ԡ
ᔂ੺൤ฌ࠱๯), a CMM standardized product extracted 
from radices Codonopsis sp. and Astragali sp. to improve 
immune function against chronic diseases.(113) PSSC, 
polysaccharides from Salvia chinensis Benth, suppressed 
growth of H22 cells and reduced serum levels of PGE2 
in mice, suggesting an anti-tumor immune-stimulatory 
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activity.(114) Two basidiomycete species, Lentinus edodes 
and Cordyceps sinensis, increased IL-2 production 
in LBRM-33 1A5 T cells, through indirect action on 
Ms, without directly acting on T cell.(115) Qingshu Yiqi 
Decoction (ຍఋᄞඡ෋), a CMM prescription consisting 
of nine herbs including Astragalus membranaeus, Panax 
ginseng and Sculellaria baicalensis, has been classically 
used for treating fever and pulmonary disorders. Tumor 
burden and losses of muscle mass were found to be 
significantly decreased when 5-FU was combined with 
this Chinese prescription, suggesting that the combination 
of S. baicalensis and QYD is able to ameliorate cachectic 
symptoms and positively stimulate anti-tumor immunity in 
mice undergoing chemotherapy.(116)
Conclusion
CM, respectively CMM, belongs to a natural 
medicine system, which is still in active practice as 
an alternative therapeutic possibility beyond the 
origin cultural region. Based on this medicine system, 
many new medications have been developed, 
such as compounds isolated from Artemisia annua, 
and minnelide (a potential anti-pancreatic cancer 
medication, modiſ ed from triptolide).(117-119)
In the last two decades, experimental and clinical 
evidence showed that most chronic diseases, including 
cancer, are caused by a dysregulated inflammatory-
immune responseὊand TAMs are a key link between 
inflammation and cancer in regulating tumor growth, 
progression and response to anticancer drugs.(120) 
CMM demonstrated obvious anti-tumor effects based 
on its characteristics of multi-components and multi-
targets. The anti-cancer properties of CMM targeting 
TAMs were shown to involve the following mechanisms: 
(1) inhibition of the production of cytokines or 
chemokines associated with TAM recruitment and 
activation; (2) promotion of Ms phenotype conversion 
from M2 to M1; (3) reduction of the production of pro-
tumoral cytokines secreted by TAM including angiogenic 
and lymphangiogenic factors;(78) (4) reshaping of the 
TME to inhibit the immunosuppressive responses.
Most ſ ndings of anti-tumor CMM targeting Ms or 
immune regulation are related to the expression level of 
cytokines or chemokines in the TME. More investigations 
are required, however, to unravel the mechanism 
involved and identify active components of CMM 
prescriptions. CMM prescriptions are highly complex 
systems, and interactions between different components 
commonly exist.(121) For example in the case of extracts 
of radices Astragalus membranaceous and Angelica 
sinensis in different proportions (e.g. w/w ratio) opposite 
effects related to cancer pulmonary metastasis were 
observed and should be investigated.(48)
In this article, we have analyzed the literature for 
studies focused on cancer therapy related to CM and 
CMM. It is not just limited to active single substances, 
classical prescriptions, but it also includes combinations 
with conventional therapies, and the putative targeting 
phase in cancer development as listed in Figure 1. 
Further investigations are required to better characterize 
the anti-tumor effects of CM and CMM. In order to 
develop novel anti-tumor therapies based on CMM it will 
be essential to conſ rm results obtained in in vitro studies 
addressing molecular mechanisms of action on TAMs by 
performing in vivo studies on tumor progress.(122)
Figure 1. Anti-tumor CMMs Targeting 
TAMs Effects on Tumor Progression
No tes :  P re -ma l i gnan t  o r  ma l i gnan t  ce l l s  and 
microenvironments, such as inƀ ammation or hypoxia, generated 
various cytokines, chemokines, and enzymes to recruit and 
activate macrophages. The TAMs, interacted with TME and other 
cells, re-programmed into diverse functional phenotypes to affect 
tumor initiation, metastasis, and immune suppression. Anti-tumor 
CMM compounds or prescriptions targeting TAMs could effect on 
different phases of tumor growth through different mechanism.
CMM
Microenvironment 
Pre-malignant cells
Cytokines
polypeptides
Inhibit M recruitment and activation
(Berberine, EGCG, PSP, APS, QHBJ...) 
Inhibit angiogenesis and 
lymphangiogenesis
(Berberine, EGCG, PSP, APS, QHBJ...) 
Direct effect on M  (PAC-I) 
M re-program from M2 to M1
(Emodin, ISL, SH, CL, GSP, FZJD) 
Inhibit Matrix remodeling
(Emodin, GA, Aloe emodin)
Regulation of immune system
(Salidroside, Berberine, Cucurbitacin D, 
2H-PPD, Polysaccharides, WKF, QSYQ...)
Tumor initiation
Tumor metastasis
Immune suppression
TAM
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